Erin L. Filbert

684 total citations
19 papers, 526 citations indexed

About

Erin L. Filbert is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Erin L. Filbert has authored 19 papers receiving a total of 526 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 6 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Erin L. Filbert's work include Immunotherapy and Immune Responses (8 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Immune cells in cancer (4 papers). Erin L. Filbert is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Immune cells in cancer (4 papers). Erin L. Filbert collaborates with scholars based in United States, Spain and South Korea. Erin L. Filbert's co-authors include Andréy S. Shaw, Jianping Zhao, Jiancheng Hu, Susan S. Taylor, Alexandr P. Kornev, Haiyang Yu, Diane Schmidt, Michael B. Gotway, Joseph M. McCune and Paul Baum and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Erin L. Filbert

17 papers receiving 512 citations

Peers

Erin L. Filbert
Yehudi Bloch Belgium
Florencia Cano United Kingdom
Mani Ravichandran Canada
Masaki Magari Japan
Shujuan Pan United States
Oleg V. Chaika United States
Yisong Wang China
Jinlan Gao China
Céline Garcia France
Hassan Issafras United States
Yehudi Bloch Belgium
Erin L. Filbert
Citations per year, relative to Erin L. Filbert Erin L. Filbert (= 1×) peers Yehudi Bloch

Countries citing papers authored by Erin L. Filbert

Since Specialization
Citations

This map shows the geographic impact of Erin L. Filbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin L. Filbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin L. Filbert more than expected).

Fields of papers citing papers by Erin L. Filbert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin L. Filbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin L. Filbert. The network helps show where Erin L. Filbert may publish in the future.

Co-authorship network of co-authors of Erin L. Filbert

This figure shows the co-authorship network connecting the top 25 collaborators of Erin L. Filbert. A scholar is included among the top collaborators of Erin L. Filbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin L. Filbert. Erin L. Filbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Chao, Joseph, Marcus Smith Noel, Veena Shankaran, et al.. (2025). A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers. Cancer Research Communications. 5(2). 349–357.
2.
Filbert, Erin L., Brandon K. Chen, Alexander Cheung, et al.. (2024). Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer. Cancer Research Communications. 4(1). 200–212. 6 indexed citations
3.
Barratt, Jonathan, Biruh Workeneh, Sung Gyun Kim, et al.. (2024). A Phase 1/2 Trial of Zigakibart in IgA Nephropathy. Journal of the American Society of Nephrology. 35(10S). 1 indexed citations
4.
5.
Filbert, Erin L., et al.. (2021). APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunology Immunotherapy. 70(7). 1853–1865. 22 indexed citations
6.
Weiss, Sarah A., Mario Sznol, Montaser Shaheen, et al.. (2021). 389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. SHILAP Revista de lepidopterología. A422–A422. 5 indexed citations
7.
Alvarado, Ryan, Minu K. Srivastava, Christine Tan, et al.. (2021). Abstract LB177: Targeting SIRPα with APX701, a Novel Myeloid Checkpoint Inhibitor. Cancer Research. 81(13_Supplement). LB177–LB177.
8.
Alvarado, Ryan, et al.. (2021). Abstract LB175: APX601, a Potent TNFR2 Antagonist as a Novel and Promising Approach to Reverse Tumor Immune Suppression. Cancer Research. 81(13_Supplement). LB175–LB175. 6 indexed citations
9.
Filbert, Erin L., et al.. (2020). 693 APX601, a Novel TNFR2 antagonist antibody for cancer immunotherapy. SHILAP Revista de lepidopterología. A417.1–A417. 5 indexed citations
10.
Srivastava, Minu K., Ryan Alvarado, Christine Tan, et al.. (2020). 188 Novel Anti-SIRpalpha antibodies with differentiated characteristics as promising cancer therapeutics. SHILAP Revista de lepidopterología. A111.1–A111. 1 indexed citations
11.
Björck, Pia, et al.. (2016). Abstract 5004: APX005M, a humanized anti-CD40 antibody with strong immune-modulatory activities capable of tumor eradication in vivo. Cancer Research. 76(14_Supplement). 5004–5004. 3 indexed citations
12.
Björck, Pia, et al.. (2015). The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities. Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P198–P198. 1 indexed citations
13.
Borgne, Marie Le, Erin L. Filbert, & Andréy S. Shaw. (2013). Kinase Suppressor of Ras 1 Is Not Required for the Generation of Regulatory and Memory T Cells. PLoS ONE. 8(2). e57137–e57137. 3 indexed citations
14.
Filbert, Erin L., Marie Le Borgne, Joseph Lin, John E. Heuser, & Andréy S. Shaw. (2012). Stathmin Regulates Microtubule Dynamics and Microtubule Organizing Center Polarization in Activated T Cells. The Journal of Immunology. 188(11). 5421–5427. 37 indexed citations
15.
Hu, Jiancheng, Haiyang Yu, Alexandr P. Kornev, et al.. (2011). Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proceedings of the National Academy of Sciences. 108(15). 6067–6072. 108 indexed citations
16.
Filbert, Erin L., Anhco Nguyen, Mary A. Markiewicz, et al.. (2010). Kinase suppressor of Ras 1 is required for full ERK activation in thymocytes but not for thymocyte selection. European Journal of Immunology. 40(11). 3226–3234. 5 indexed citations
17.
Pastorino, Sandra, Erin L. Filbert, Florian J. Sulzmaier, et al.. (2010). The death effector domain protein PEA‐15 negatively regulates T‐cell receptor signaling. The FASEB Journal. 24(8). 2818–2828. 16 indexed citations
18.
Napolitano, Laura A., Diane Schmidt, Michael B. Gotway, et al.. (2008). Growth hormone enhances thymic function in HIV-1–infected adults. Journal of Clinical Investigation. 118(3). 1085–98. 142 indexed citations
19.
Shaw, Andréy S. & Erin L. Filbert. (2008). Scaffold proteins and immune-cell signalling. Nature reviews. Immunology. 9(1). 47–56. 164 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yehudi Bloch Breakdown of academic impact, for papers by Florencia Cano Breakdown of academic impact, for papers by Mani Ravichandran Breakdown of academic impact, for papers by Masaki Magari Breakdown of academic impact, for papers by Shujuan Pan Breakdown of academic impact, for papers by Oleg V. Chaika Breakdown of academic impact, for papers by Yisong Wang Breakdown of academic impact, for papers by Jinlan Gao Breakdown of academic impact, for papers by Céline Garcia Breakdown of academic impact, for papers by Hassan Issafras
Rankless by CCL
2026